Biofrontera Logo
DE0006046113
604611
B8F.DE

Biofrontera

Kurser indlæses...

Prognose

Køb
  1
Behold
  0
Sælg
  0

Diskussioner i communityet

Der er endnu ingen diskussion om dette aktiv.

Start diskussion

  • Biofrontera receives FDA approval for Ameluz for superficial basal cell carcinoma

    The FDA has approved an expanded indication for the topical gel Ameluz (10% aminolevulinic acid hydrochloride) for photodynamic therapy of superficial basal cell carcinoma in combination with BF‑RhodoLED lamps. Ameluz is thus the first drug approved by the FDA for photodynamic therapy of a type of skin cancer. In the phase‑3 study, 66% of patients treated with Ameluz‑PDT met the primary endpoint versus 5% with placebo; histological clearance was 76% versus 19%. Biofrontera plans to launch the product for this indication in late Q4 2026 to Q1 2027 through its existing sales organization. » Mere på de.investing.com


  • Biofrontera raises gross margin to 80% as revenue grows 17% in Q1 2026

    Biofrontera reports a 17% revenue increase in Q1 2026 to $10.1 million and a gross margin of 80% versus 62% a year earlier, driven by higher Ameluz sales and price increases. Operating loss narrowed slightly; net loss was $4.8 million, or $0.41 per share. Management attributes the margin improvement to a strategic transaction and a new earn-out structure and expects 2026 revenue to reach $46.76 million with positive EPS in Q4 2026. » Mere på de.investing.com


  • Biofrontera posts record revenue and first profitable quarter in Q4 2025

    Biofrontera reports record revenue of USD 17.1 million in Q4 2025 (+36% year-on-year) and its first net profit of USD 5.6 million. The cost structure improved markedly following a strategic transaction with Biofrontera AG, reducing COGS by 45% and lifting the gross margin to 82%; adjusted EBITDA was USD 4.9 million (29% margin). The pre-market share price rose 7.07% to USD 0.93. Management expects further revenue growth and full realization of the cost benefits in 2026, as well as upside potential from product developments and possible FDA approvals. » Mere på de.investing.com


  • Biofrontera completes phase‑1 study of Ameluz for body sites

    Biofrontera has completed the pharmacokinetic phase‑1 study of Ameluz in actinic keratoses on the neck, trunk and extremities; 17 patients received treatment and blood samples were analyzed over 10 hours. The data will feed into the planned supplemental new drug application (sNDA) to the FDA, which the company expects in summer 2026, to expand the indication beyond the face and scalp. In parallel, the approval plan includes results from a recently completed phase‑3 study; financially, Biofrontera reported declining revenue and a higher net loss, while Benchmark maintained its buy recommendation with a target price of USD 3.00. » Mere på de.investing.com


  • Biofrontera files sNDA with FDA for Ameluz‑PDT to treat superficial basal cell carcinoma

    Biofrontera has submitted a supplemental new drug application (sNDA) to the FDA for Ameluz‑PDT to treat superficial basal cell carcinoma. The submission is based on a phase‑3 study of 187 patients that showed a cure rate of 65.5% versus 4.8% in the placebo group and complete histological clearance in 75.9% versus 19%; one‑year follow‑up also documented low recurrence rates. The goal is to expand approval into cutaneous oncology and to use the treatment with the BF‑RhodoLED and RhodoLED XL red‑light lamps. Despite annual sales of $37.16 million and a high gross margin, Biofrontera is not yet profitable; the company recently reported declining revenue and higher net losses, although analysts continue to maintain buy recommendations. » Mere på de.investing.com

I 2022 har Biofrontera allerede udloddet 0,26 € i udbytte. Den seneste udlodning fandt sted i marts 2022.

Virksomhedstal

I det seneste år havde Biofrontera en omsætning på 32,25 mio. € og et nettoresultat på -369 t €
(EUR) 2023
YoY
Omsætning 32,25 mio. 25,30 %
Bruttofortjeneste 25,37 mio. 20,91 %
Nettoresultat -369 t 99,16 %
EBITDA 5,57 mio. 138,47 %

Fundamentale data

Nøgletal Værdi
Markedsværdi
20,67 mio. €
Antal aktier
3,04 mio.
Højeste/laveste i 52 uger
22,58 € - 0,30 €
Udbytte Nej
Beta
0,64
P/E (PE Ratio)
-1,42
PEG (PEG Ratio)
-0,01
K/I (PB Ratio)
-35,84
P/S (PS Ratio)
0,18

Virksomhedsprofil

Biofrontera AG er en biofarmaceutisk virksomhed, der udfører forskning, udvikling og markedsføring af dermatologiske produkter. Virksomhedens produkter omfatter Ameluz og BF-RhodoLED-lampen til behandling af milde og moderate aktiniske keratoser i ansigt og hovedbund, feltkancerisering og fatale pladecellekarcinomer. Virksomheden udvikler også RhodoLED XL til behandling af flere spredte læsioner; Belixos, et moderne aktivt kosmetisk produkt til irriteret og følsom hud; og Xepi til behandling af antibiotikaresistente bakterier. Den tilbyder primært sine produkter i USA, Europa og Israel. Virksomheden har en samarbejds- og partneraftale med Maruho Co., Ltd. Biofrontera AG blev grundlagt i 1997 og har hovedkontor i Leverkusen, Tyskland.

Navn
Biofrontera
CEO
Pilar de la Huerta Martinez
Hjemsted Leverkusen,
Tyskland
Websted
Sektor
Sundhed
Branche
Lægemidler
Børsnotering
31.10.2006
Medarbejdere 91

Tickersymboler

Børs Symbol
XETRA
B8F.DE
Pnk
BFFTF
Frankfurt
B8FK.F
🍪

Parqet  bruger cookies. Læs mere